Free tool
FAERS Monitor: Sandostatin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019667 or its brand name (Sandostatin, Octreotide Acetate). Reports on generic versions are filed under their own applications.
Reports
9,636
Serious
7,955
83% of reports
Hospitalization
3,835
Death reported
1,880
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea2,155
- fatigue1,847
- blood pressure increased1,658
- nausea1,529
- blood pressure systolic increased1,409
- malaise1,232
- abdominal pain1,227
- death1,219
- pain1,197
- injection site pain1,138
- asthenia1,064
- weight decreased1,043
- dizziness1,032
- malignant neoplasm progression1,026
- vomiting1,019
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 111 |
| 2005 | 101 |
| 2006 | 119 |
| 2007 | 102 |
| 2008 | 144 |
| 2009 | 187 |
| 2010 | 291 |
| 2011 | 319 |
| 2012 | 346 |
| 2013 | 255 |
| 2014 | 372 |
| 2015 | 559 |
| 2016 | 531 |
| 2017 | 649 |
| 2018 | 795 |
| 2019 | 1,050 |
| 2020 | 1,100 |
| 2021 | 602 |
| 2022 | 561 |
| 2023 | 526 |
| 2024 | 402 |
| 2025 | 271 |
| 2026 | 243 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,523 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure systolic increasedSignal | 1,409 | 169.9 | 161.6 | 219,581 |
| blood pressure increasedSignal | 1,658 | 23.9 | 22.9 | 36,258 |
| malignant neoplasm progressionSignal | 1,026 | 22.1 | 20.8 | 20,520 |
| abdominal painSignal | 1,227 | 11.6 | 11.0 | 11,905 |
| weight decreasedSignal | 1,043 | 8.2 | 7.7 | 6,631 |
| injection site painSignal | 1,138 | 8.1 | 7.7 | 7,181 |
| diarrhoeaSignal | 2,155 | 7.3 | 7.0 | 12,058 |
| astheniaSignal | 1,064 | 6.2 | 5.8 | 4,697 |
| malaiseSignal | 1,232 | 6.1 | 5.8 | 5,401 |
| fatigueSignal | 1,847 | 5.2 | 5.0 | 6,465 |
| vomitingSignal | 1,019 | 4.7 | 4.5 | 3,064 |
| dizzinessSignal | 1,032 | 4.5 | 4.3 | 2,892 |
| painSignal | 1,197 | 4.3 | 4.0 | 3,066 |
| nauseaSignal | 1,529 | 4.2 | 4.0 | 3,897 |
| deathSignal | 1,219 | 3.1 | 2.9 | 1,794 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.